Celltrion Healthcare (091990 KS): Portfolio Enhancement to Drive Business Growth

345 Views19 Jun 2023 00:19

Tina has highlighted this Insight as a Top Pick

SUMMARY

Celltrion Healthcare (091990 KS) is expected to launch Humira biosimilar, Yuflyma, in the U.S. market in July 2023. Despite heavy competition, as high-concentration citrate-free formulation, Yuflyma has competitive edge.
In April 2023, Celltrion has launched bevacizumab biosimilar, Vegzelma in the U.S. Vegzelma will be the first product that the company will be directly selling in the U.S.
Through portfolio expansion, Celltrion increased target market size to $53.7B in 2023 from $20.6B in 2020, representing 161% growth. For 2024, the target market is expected to increase to $91.3B.

Get started on the Smartkarma Research Network with a complimentary Preview Pass to:

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Rising

Global Healthcare Analyst

Health CareEquity Bottom-UpThematic (Sector/Industry)

Insight Stream